2W3I

Crystal Structure of FXa in complex with 4,4-disubstituted pyrrolidine-1,2-dicarboxamide inhibitor 2

Summary for 2W3I

• Entry DOI: 10.2210/pdb2w3i/pdb
• Related: 1C5M 1EZQ 1F0R 1F0S 1FAX 1FJS 1G2L 1G2M 1HCG 1IOE 1IQE 1IQF 1IQG 1IQH 1IQI 1IQJ 1IQK 1IQL 1IQM 1IQN 1KSN 1KYE 1LPG 1LPK 1LPZ 1LQD 1MQ5 1MQ6 1MSX 1NFU 1NFW 1NFX 1NFY 1NL8 1P0S 1V3X 1WU1 1XKA 1XKB 1Z6E 2BMG 2BOH 2BOK 2BQ6 2BQ7 2BQW 2CJI 2FZZ 2G00 2GD4 2J2U 2J34 2J38 2J4I 2J94 2J95 2JKH 2UWL 2UWO 2UWP 2VH0 2VH6 2VVC 2VVU 2VVV 2VWL 2VWM 2VWN 2VWO 2W26 2W3K
• Descriptor: COAGULATION FACTOR X, HEAVY CHAIN, COAGULATION FACTOR X, LIGHT CHAIN, CALCIUM ION, ... (5 entities in total)
• Functional Keywords: drug design, glycoprotein, hydroxylation, blood clotting, serine protease, egf-like domain, fxa coagulation factor inhibitor, zymogen, protease, secreted, hydrolase, blood coagulation, gamma-carboxyglutamic acid, cleavage on pair of basic residues
• Biological source: HOMO SAPIENS (HUMAN); More
• Cellular location: Secreted: P00742 P00742
• Total number of polymer chains: 2
• Total formula weight: 32513.19

Authors

Zhang, E.,Mochalkin, I.,Casimiro-Garcia, A.,Van Huis, C.A. (deposition date: 2008-11-12, release date: 2009-04-07, Last modification date: 2023-12-13)

Primary citation

Van Huis, C.A.,Casimiro-Garcia, A.,Bigge, C.F.,Cody, W.L.,Dudley, D.A.,Filipski, K.J.,Heemstra, R.J.,Kohrt, J.T.,Leadley, R.J.J.,Narasimhan, L.S.,Mcclanahan, T.,Mochalkin, I.,Pamment, M.,Peterson, J.T.,Sahasrabudhe, V.,Schaum, R.P.,Edmunds, J.J.
Exploration of 4,4-Disubstituted Pyrrolidine-1,2-Dicarboxamides as Potent, Orally Active Factor Xa Inhibitors with Extended Duration of Action.
Bioorg.Med.Chem., 17:2501-, 2009

PubMed Abstract: Aiming to improve upon previously disclosed Factor Xa inhibitors, a series of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides were explored with the intent of increasing the projected human half-life versus 5 (projected human t(1/2)=6 h). A stereospecific route to compounds containing a 4-aryl-4-hydroxypyrrolidine scaffold was developed, resulting in several compounds that demonstrated an increase in the half-life as well as an increase in the in vitro potency compared to 5. Reported herein is the discovery of 26, containing a (2R,4S)-4-hydroxy-4-(2,4-difluorophenyl)-pyrrolidine scaffold, which is a selective, orally bioavailable, efficacious Factor Xa inhibitor that appears suitable for a once-daily dosing (projected human t(1/2)=23 h).

PubMed: 19231206
DOI: 10.1016/J.BMC.2009.01.063

Experimental method

X-RAY DIFFRACTION (1.9 Å)